Harvard Bioscience, Inc. (NASDAQ:HBIO) CEO Buys $53,400.00 in Stock

Harvard Bioscience, Inc. (NASDAQ:HBIO – Get Rating) CEO James W. Green acquired 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 14th. The shares were bought at an average price of $2.67 per share, with a total value of $53,400.00. Following the acquisition, the chief executive officer now directly owns 2,866,052 shares of the company’s stock, valued at approximately $7,652,358.84. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Harvard Bioscience Price Performance

Shares of NASDAQ:HBIO opened at $3.01 on Friday. The company has a quick ratio of 1.06, a current ratio of 2.20 and a debt-to-equity ratio of 0.60. The firm has a market capitalization of $126.99 million, a PE ratio of -13.09 and a beta of 1.55. Harvard Bioscience, Inc. has a twelve month low of $1.98 and a twelve month high of $6.49. The company has a 50-day moving average price of $2.88 and a two-hundred day moving average price of $2.70.

Hedge Funds Weigh In On Harvard Bioscience

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Arbitrage SA boosted its position in Harvard Bioscience by 47.6% during the second quarter. BNP Paribas Arbitrage SA now owns 9,920 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 3,200 shares during the period. Prudential Financial Inc. bought a new position in shares of Harvard Bioscience in the second quarter valued at approximately $37,000. Public Employees Retirement System of Ohio bought a new position in shares of Harvard Bioscience in the third quarter valued at approximately $40,000. Lazard Asset Management LLC boosted its position in shares of Harvard Bioscience by 68.4% in the second quarter. Lazard Asset Management LLC now owns 11,989 shares of the medical instruments supplier’s stock valued at $43,000 after acquiring an additional 4,869 shares during the period. Finally, Virtu Financial LLC bought a new position in shares of Harvard Bioscience in the third quarter valued at approximately $46,000. Institutional investors own 69.37% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on HBIO shares. StockNews.com upgraded shares of Harvard Bioscience from a “hold” rating to a “buy” rating in a report on Monday, March 13th. Benchmark increased their target price on shares of Harvard Bioscience from $3.00 to $4.00 and gave the stock a “buy” rating in a research report on Friday, March 10th.

About Harvard Bioscience

(Get Rating)

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. It operates under the geographical segments: United States, Germany, United Kingdom, and Rest of the world. It sells its products through catalog, Website, distributors, and direct sales force.